Europe
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
Called “blastoids,” the alternative embryo-like structures are grown for up to 13 days in the lab for use in different types of studies on the behavior of human embryos.
Novartis held an investor event to discuss their research programs, highlighting its partnership with Belgian pharma company UCB worth up to $1.5 billion.
GlaxoSmithKline said early research shows its monoclonal antibody is demonstrating efficacy against the newest strain of COVID-19.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The takeover is part of the French biotech giant’s “Play to Win” strategy of growing its global vaccines pipeline through the acquisition of promising projects and companies.
Pfizer veteran Phil Dormitzer will assume the role of Global Head of Vaccines beginning Friday.
Quell Therapeutics scooped up $156 million in a Series B round this week. The company utilizes regulatory T cells to treat a variety of autoimmune and inflammatory diseases.
The World Health Organization officially declared omicron – aka. B.1.1.529 – a variant of concern (VOC) on Friday.
Bonus BioGroup’s product is back in the news again as its cell therapy promises to treat late-stage COVID-19.
PRESS RELEASES